Bamlanivimab is authorized by Health Canada (in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19) to treat adult and pediatric patients 12 years of age or older with mild to moderate COVID-19, who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization. The drug is administered intravenously.

This report provides a review of issues that require consideration for the prioritization and optimization of the use of bamlanivimab in Canadian health systems. A synthesis of information is presented to summarize different perspectives on implementation of this therapy, such as available guidelines and appraisals by other health technology assessment agencies.

The report includes the perspectives of a panel of interdisciplinary clinical specialists with experience in the treatment of patients with symptoms of COVID-19. This panel was convened by CADTH to explore different perspectives regarding the use of bamlanivimab in Canada.

This work was undertaken to support the pandemic response, where evidence-informed perspectives may be useful to support decision-making.

Link to Report

CADTH Drug Implementation Advice: Bamlanivimab for Mild-to-Moderate Symptoms of COVID-19

Related Reports

Bamlanivimab in the Treatment of Outpatients With COVID-19: A Critical Appraisal of an Interim Analysis of the BLAZE-1 Trial

Horizon Scan: Virus-neutralizing monoclonal antibodies against SARS-CoV-2

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.